Delta Biopharma Profile
Key Indicators
- Authorised Capital ₹ 50.20 Cr
as on 31-07-2024
- Paid Up Capital ₹ 50.00 Cr
as on 31-07-2024
- Company Age 12 Year, 16 Days
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.70 Cr
as on 31-07-2024
- Revenue 39.36%
(FY 2023)
- Profit -132.42%
(FY 2023)
- Ebitda -56.83%
(FY 2023)
- Net Worth -27.55%
(FY 2023)
- Total Assets -3.62%
(FY 2023)
About Delta Biopharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 50.20 Cr and a paid-up capital of Rs 50.00 Cr.
The company currently has active open charges totaling ₹2.70 Cr.
The Key Managerial Personnel (KMP) at Delta Biopharma Private Limited India is Jyoti Rani as COMPANY SECRETARY. Rajiv Khanna, Rita Khanna, Chander Khanna, and One other member serve as directors at the Company.
- CIN/LLPIN
U24100MH2012PTC238604
- Company No.
238604
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Dec 2012
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Delta Biopharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Jyoti Rani | Company Secretary | 01-Nov-2018 | Current |
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajiv Khanna  | Director | 31-Mar-2015 | Current |
Rita Khanna  | Director | 08-Dec-2012 | Current |
| Chander Khanna | Director | 08-Dec-2012 | Current |
| Rajat Khanna | Director | 08-Dec-2012 | Current |
Financial Performance of Delta Biopharma.
Delta Biopharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 39.36% increase. The company also saw a substantial fall in profitability, with a 132.42% decrease in profit. The company's net worth observed a substantial decline by a decrease of 27.55%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Delta Biopharma?
In 2023, Delta Biopharma had a promoter holding of 28.71% and a public holding of 71.29%. The company had 1 Subsidiary. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Zifam Pinnacle Healthcare Private LimitedActive 14 years 11 monthsRajiv Khanna, Rita Khanna and 1 more are mutual person
Era Pharmaceuticals Private LimitedActive 20 years 8 monthsRita Khanna and Chander Khanna are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 26 Mar 2022 | ₹2.70 Cr | Open |
How Many Employees Work at Delta Biopharma?
Delta Biopharma has a workforce of 153 employees as of Jul 31, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Delta Biopharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Delta Biopharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
